SCHEDULE: Soleus Entities Disclose 9.99% Stake in C4 Therapeutics

Soleus Capital Management and affiliated entities report a significant beneficial ownership stake of 9.99% in C4 Therapeutics, Inc., including warrants.

Summary

• Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy collectively reported beneficial ownership of 10,334,114 shares of C4 Therapeutics, Inc. common stock.
• This aggregate ownership represents 9.99% of the Issuer's common stock outstanding.
• The reported shares include warrants to purchase up to 6,530,172 shares of common stock, reflecting beneficial ownership limitations.
• Soleus Capital Master Fund, L.P. and its related entities (Soleus Capital, LLC, Soleus Capital Group, LLC) beneficially own 10,361,860 shares, also representing 9.99% of the class, including warrants to purchase up to 6,807,911 shares.
• Soleus Private Equity Fund III, L.P. and its related entities (Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC) beneficially own 6,072,822 shares, representing 5.9% of the class, including warrants to purchase up to 5,822,829 shares.
• The percentage of class is calculated based on 96,914,418 shares of common stock outstanding as of October 29, 2025, as reported in the Issuer's Form 10-Q.
• The reporting persons disclaim beneficial ownership of these shares for purposes other than determining their obligations under Section 13(d) of the Exchange Act.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive disclosure, as a significant institutional investor maintaining a near-10% stake, including warrants, suggests continued confidence in C4 Therapeutics, Inc. without indicating any immediate negative developments.

Positives

• A significant institutional investor group, Soleus Capital Management and its affiliates, holds a substantial stake, potentially indicating confidence in C4 Therapeutics' long-term prospects.
• The beneficial ownership includes a considerable number of warrants, suggesting a prior investment with potential for future equity conversion.

Negatives

• The filing itself does not contain negative operational or financial information, as it is solely an ownership disclosure.

Risks

• The concentration of a significant percentage of shares (9.99%) in the hands of a single institutional investor group could lead to increased influence over corporate decisions, although the filing states the securities were not acquired for changing or influencing control.
• The existence of warrants, while a positive for the holder, could lead to dilution for existing shareholders upon exercise, depending on the strike price relative to the market price.

Future Outlook

The filing is an ownership disclosure and does not contain forward-looking statements or guidance from C4 Therapeutics, Inc. or the reporting persons regarding the Issuer's future performance.

Industry Context

StockSavvy.ai notes that significant institutional ownership, such as the 9.99% stake disclosed by Soleus Capital Management, is common in the biotechnology sector, where specialized funds often take substantial positions in promising early to mid-stage companies like C4 Therapeutics. This level of ownership can signal investor confidence in the company's drug pipeline and strategic direction, potentially attracting further institutional interest.

Comparison to Industry Standards

• A 9.99% stake by an institutional investor group is a substantial position, often seen as a strong vote of confidence, particularly in the biotech industry where capital-intensive R&D requires robust investor backing.
• Compared to typical passive institutional holdings, a near-10% stake suggests a more engaged, albeit non-controlling, interest, similar to significant positions held by funds like ARK Invest in innovative tech/biotech firms or BlackRock in large-cap companies, though the scale and intent (passive vs. activist) can differ.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a substantial stake may be perceived positively, potentially bolstering investor confidence and signaling long-term interest in the company.
• Management: Awareness of a large, passive institutional holder may influence strategic decisions, though the filing explicitly disclaims intent to influence control.

Key Dates

Recommendation

The filing is a routine ownership disclosure (Schedule 13G) indicating a significant, but passive, institutional stake. While a large institutional holding can be a positive signal, this filing does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms an existing substantial investment, suggesting a 'hold' position for investors awaiting further fundamental news from C4 Therapeutics.

Keywords

C4 Therapeutics, Soleus Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Warrants, Equity Stake, Biotechnology, SEC Filing